Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters








Language
Year range
1.
Singapore medical journal ; : 473-475, 2014.
Article in English | WPRIM | ID: wpr-244803

ABSTRACT

We report five cases of non-arteritic anterior ischaemic optic neuropathy (NA-AION) where spontaneous resolution of the optic disc swelling occurred, and all relevant visual modalities were normal at presentation and remained so until resolution of the process after a median time of 9.6 weeks. This condition, which can be termed 'incipient NA‑AION' or 'threatened NA-AION', should be recognised so that unnecessary investigations for other and more serious causes of optic disc swelling can be prevented.


Subject(s)
Adult , Female , Humans , Male , Middle Aged , Adrenergic alpha-2 Receptor Agonists , Therapeutic Uses , Brimonidine Tartrate , Therapeutic Uses , Diagnosis, Differential , Ophthalmic Solutions , Optic Disk , Pathology , Optic Neuropathy, Ischemic , Diagnosis , Singapore , Time Factors , Vision, Ocular , Visual Acuity
2.
Chinese Journal of Cancer ; (12): 327-335, 2011.
Article in English | WPRIM | ID: wpr-294516

ABSTRACT

Overexpression of human epidermal growth factor receptor-2 (HER2) in metastatic breast cancer (MBC) is associated with poor prognosis. This single-arm open-label trial (EGF109491; NCT00508274) was designed to confirm the efficacy and safety of lapatinib in combination with capecitabine in 52 heavily pretreated Chinese patients with HER2-positive MBC. The primary endpoint was clinical benefit rate (CBR). Secondary endpoints included progression-free survival (PFS), time to response (TTR), duration of response (DoR), central nervous system (CNS) as first site of relapse, and safety. The results showed that there were 23 patients with partial responses and 7 patients with stable disease, resulting in a CBR of 57.7%. The median PFS was 6.34 months (95% confidence interval, 4.93-9.82 months). The median TTR and DoR were 4.07 months (range, 0.03-14.78 months) and 6.93 months (range, 1.45-9.72 months), respectively. Thirteen (25.0%) patients had new lesions as disease progression. Among them, 2 (3.8%) patients had CNS disease reported as the first relapse. The most common toxicities were palmar-plantar erythrodysesthesia (59.6%), diarrhea (48.1%), rash (48.1%), hyperbilirubinemia (34.6%), and fatigue (30.8%). Exploratory analyses of oncogenic mutations of PIK3CA suggested that of 38 patients providing a tumor sample, baseline PIK3CA mutation status was not associated with CBR (P = 0.639) or PFS (P = 0.989). These data confirm that the lapatinib plus capecitabine combination is an effective and well-tolerated treatment option for Chinese women with heavily pretreated MBC, irrespective of PIK3CA status.


Subject(s)
Adult , Aged , Female , Humans , Middle Aged , Antineoplastic Combined Chemotherapy Protocols , Therapeutic Uses , Asian People , Breast Neoplasms , Drug Therapy , Genetics , Metabolism , Pathology , Capecitabine , Class I Phosphatidylinositol 3-Kinases , Deoxycytidine , Diarrhea , Disease Progression , Disease-Free Survival , Exanthema , Fluorouracil , Hand-Foot Syndrome , Mutation , Neoplasm Staging , Phosphatidylinositol 3-Kinases , Genetics , Quinazolines , Receptor, ErbB-2 , Metabolism , Remission Induction
SELECTION OF CITATIONS
SEARCH DETAIL